We are monitoring the impact of COVID-19 on North America HIV Therapeutics Market Get in touch with us for detailed analysis Know More
Share on

North America HIV Therapeutics Market Research Report – Segmented By Type, Application & Country (The United States, Canada & Rest of North America) – Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 1981
Pages: 118

North America HIV Therapeutics Market Size (2022 to 2027)

The size of the North American HIV therapeutics market is forecasted to worth USD 5.46 billion in 2022 and USD 5.77 billion by 2027, witnessing a CAGR of 1.1% from 2022 to 2027. The prevalence of HIV infections majorly drives the North American HIV therapeutics market growth.

HIV infections are becoming more common, especially among youth, as a result of unsafe sexual activities.

An increase in the incidence of diagnosis and treatment and a rise in the use of advanced therapies are aiding the growth of the HIV medications market in North America. Another factor aiding the growth of the HIV medicines market in North America is a greater diagnosis and treatment rate, along with a spike in the use of advanced therapies. The North American region now has one of the strongest economies, which has resulted in a well-established healthcare system.; this is one of the main drivers of the HIV medication market's development in the region. Exposure to needles or syringes contaminated with infected body fluids or tissues and lack of awareness regarding transmission risk factors are the two primary factors influencing the market growth. Furthermore, the US and Canadian governments are continuously offering assistance by investing funds to research and develop safer and more effective HIV medicines. However, Antiretroviral medicines have made a significant difference in HIV patients' survival rates and quality of life. These medicines aid the immune system in keeping virus levels low and preventing infections, resulting in a longer life expectancy for patients. Antiretrovirals can help to rebuild the immune system, restore health, and prevent the spread of AIDS and AIDS-related diseases.

In addition, government initiatives to enhancing public knowledge of HIV cause, symptoms, treatment choices, and the critical role of these therapies in controlling HIV growth are intensifying. As a result, the HIV medication industry is anticipated to develop due to increased awareness of government activities. The government's and other NGOs' coordinated efforts to offer at-risk individuals improved access to disease testing and treatment for infected persons are a critical element driving the HIV-1 market growth. In addition, the introduction of long-acting injectable treatments, as well as the ongoing popularity of single-tablet regimens (STRs), will propel the market forward.

However, the North American HIV therapeutics market is expected to be constrained by government rules governing the licensing and commercialization of HIV treatments.

This research report on the North American HIV Therapeutics Market is segmented & sub-segmented the market into the following categories:

By Type:

  • Nucleoside/Tide Reverse Transcriptase Inhibitors
  • Nucleoside/Tide Analogues
  • Non-Nucleoside Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Integrase Inhibitors
  • CCR5 Inhibitors
  • Fusion Inhibitors

By Application:

  • HIV Type-1
  • HIV Type-2

By Country:

  • United States
  • Canada
  • Rest of North America

Geographically, The North American HIV Therapeutics Market is forecasted to account for the most significant share in the global market during the forecast period. Over the period, the development of the HIV medicines market in North America is aided by an increase in the incidence of diagnosis and treatment and increased usage of advanced therapies. Pharmaceutical firms endeavor to address this problem by creating injectable treatments that are given less often than the market-leading oral medications taken daily and have been associated with side effects like osteoporosis, hepatotoxicity, and renal failure. The largest growth contributors such as The U.S. and Canada are augmenting the market revenue in the region. The U.S. and Canadian governments continue to provide a helping hand by investing funding in the research and development of safer and more effective HIV medicines.

In North America, the U.S. HIV Therapeutics Market is expected to play a dominating role due to the increasing healthcare spending, investments in research and development activities, and advancing healthcare infrastructure. However, the Canadian HIV Therapeutics Market is predicted to record a promising share in the coming years.

KEY MARKET PLAYERS:

A few of the noteworthy companies operating in the North American HIV Therapeutics Market profiled in this report are GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Merck, Hoffmann-La Roche, and Gilead Sciences.

1.Introduction               

                1.1 Market Definition 

                1.2 Study Deliverables                                                                  

                1.3 Base Currency, Base Year and Forecast Periods       

                1.4 General Study Assumptions                                                                

2. Research Methodology                        

                2.1 Introduction            

                2.2 Research Phases   

                                2.2.1 Secondary Research                                                           

                                2.2.2 Primary Research                                                 

                                2.2.3 Econometric Modelling                                                      

                                2.2.4 Expert Validation                                                  

                2.3 Analysis Design      

                2.4 Study Timeline       

3. Overview                    

                3.1 Executive Summary                                                                

                3.2 Key Inferences      

                3.3 Epidemology                                                                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                 

                4.1 Market Drivers       

                4.2 Market Restraints 

                4.3 Key Challenges      

                4.4 Current Opportunities in the Market           

5. Market Segmentation                           

                5.1 Drug Class

                                5.1.1 Introduction                                                           

                                5.1.2 integrase inhibitor                                                               

                                5.1.3 nucleoside/nucleotide reverse transcriptase inhibitor                                                         

                                5.1.4  non-nucleoside turn around transcriptase inhibitor                                                             

                                5.1.5 HIV-1 protease inhibitor                                                    

                                5.1.6 pharmacokinetic enhancer                                                              

                                5.1.7 passage inhibitor                                                  

                                5.1.8  Y-o-Y Growth Analysis, Drug class                                                                

                                5.1.9  Market Attractiveness Analysis, Drug class                                                              

                                5.1.10  Market Share Analysis, Drug class                                                              

                5.2 Application                                                                 

                                5.2.1 Introduction                                                           

                                5.2.2 HIV Type-1                                                              

                                5.2.3 HIV Type-2                                                              

                                5.2.4 Y-o-Y Growth Analysis, Application                                                               

                                5.2.5 Market Attractiveness Analysis, Application                                                             

                                5.2.6 Market Share Analysis, Application                                                              

6. Geographical Analysis                           

                6.1 Introduction            

                                6.1.1 Regional Trends                                                    

                                6.1.2 Impact Analysis                                                     

                                6.1.3 Y-o-Y Growth Analysis                                                        

                                                6.1.3.1 By Geographical Area                                     

                                                6.1.3.2 Drug Class                                            

                                                6.1.3.3 HIV TYPE 1&2                                      

                                6.1.4  Market Attractiveness Analysis                                                     

                                                6.1.4.1 By Geographical Area                                     

                                                6.1.4.2 Drug Class                                            

                                                6.1.4.3 HIV TYPE 1&2                                      

                                6.1.5  Market Share Analysis                                                      

                                                6.1.5.1 By Geographical Area                                     

                                                6.1.5.2 Drug Class                                            

                                                6.1.5.3 HIV TYPE 1&2                                      

                6.2 United States         

                6.3 Canada      

7.Strategic Analysis                     

                7.1 PESTLE analysis      

                                7.1.1 Political                                                     

                                7.1.2 Economic                                                 

                                7.1.3 Social                                                         

                                7.1.4 Technological                                                         

                                7.1.5 Legal                                                          

                                7.1.6 Environmental                                                       

                7.2 Porter’s Five analysis           

                                7.2.1 Bargaining Power of Suppliers                                                        

                                7.2.2 Bargaining Power of Consumers                                                    

                                7.2.3 Threat of New Entrants                                                     

                                7.2.4 Threat of Substitute Products and Services                                                              

                                7.2.5 Competitive Rivalry within the Industry                                                     

8.Market Leaders' Analysis                      

                8.1 Athersys   

                                8.1.1 Overview                                                 

                                8.1.2 Product Analysis                                                   

                                8.1.3 Financial analysis                                                  

                                8.1.4 Recent Developments                                                       

                                8.1.5 SWOT analysis                                                       

                                8.1.6 Analyst View                                                          

                8.2 StemCells 

                8.3 Cryo Cell International        

                8.4 Geron Corporation                                                                  

                8.5 Mesoblast

                8.6 Aastrom Biosciences           

                8.7 Celgene Corporation           

                8.8 Invitrogen

                8.9 Cytori Therapeutics                                                                 

                8.10 Retractable Technologies

9.Competitive Landscape                         

                9.1 Market share analysis         

                9.2 Merger and Acquisition Analysis    

                9.3 Agreements, collaborations and Joint Ventures      

                9.4 New Product Launches      

10.Market Outlook and Investment Opportunities                       

Appendix                        

                a) List of Tables                                                                

                b) List of Figures                                                            

  1. North America HIV Therapeutics Market, By Type, From 2022 - 2027 (USD Billion)
  2. North America Nucleoside/tide reverse transcriptase inhibitors or nucleoside/tide analogues Market, By Region, From 2022 - 2027 (USD Billion)
  3. North America Non-nucleoside reverse transcriptase inhibitors Market, By Region, From 2022 - 2027 (USD Billion)
  4. North America Protease inhibitors Market, By Region, From 2022 - 2027 (USD Billion)
  5. North America Integrase [strand transfer] inhibitors Market, By Region, From 2022 - 2027 (USD Billion)
  6. North America Fusion inhibitors Market, By Region, From 2022 - 2027 (USD Billion)
  7. North America HIV Therapeutics Market, By Application, From 2022 - 2027 (USD Billion)
  8. North America HIV Type 1 Market, By Region, From 2022 - 2027 (USD Billion)
  9. North America HIV Type 2 Market, By Region, From 2022 - 2027 (USD Billion)
  10. United States HIV Therapeutics Market, By Type, From 2022 - 2027 (USD Billion)
  11. United States HIV Therapeutics Market, By Application, From 2022 - 2027 (USD Billion)
  12. Canada HIV Therapeutics Market, By Type, From 2022 - 2027 (USD Billion)
  13. Canada HIV Therapeutics Market, By Application, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample